Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03430011 · OUTCOME

Duration of Hospitalization From JCARH125 Administration in Phase 2

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2024-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
Full Range
Time frame
From JCARH125 infusion to up to approximately 61 months

What was measured

Total length of all intensive care unit (ICU) and non-ICU stays from JCARH125 Administration. ICU inpatient and non-ICU inpatient are not exclusive. Total length includes participants who had multiple hospitalization stays.

Analysis population: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol

Groups in this outcome

Phase 2 600 x 10^6 Cells

JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 2 600 x 10^6 Cells24

Reported measurements

ICU inpatient

Analysis denominator · Participants

GroupSource count
Phase 2 600 x 10^6 Cells9
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Phase 2 600 x 10^6 Cells9.0Not reported332Not reported
non-ICU inpatient

Analysis denominator · Participants

GroupSource count
Phase 2 600 x 10^6 Cells21
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Phase 2 600 x 10^6 Cells11.0Not reported658Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        32
        value
        9.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      units
      Participants
    title
    ICU inpatient
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6
        upper Limit
        58
        value
        11.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        21
      units
      Participants
    title
    non-ICU inpatient
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
Total length of all intensive care unit (ICU) and non-ICU stays from JCARH125 Administration. ICU inpatient and non-ICU inpatient are not exclusive. Total length includes participants who had multiple hospitalization stays.
dispersion Type
Full Range
groups
  1. description
    JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
    id
    OG000
    title
    Phase 2 600 x 10^6 Cells
param Type
MEDIAN
population Description
All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
reporting Status
POSTED
time Frame
From JCARH125 infusion to up to approximately 61 months
title
Duration of Hospitalization From JCARH125 Administration in Phase 2
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice